Cycurion Announces Approximately $800,000 in Annual Contract Spend, Accelerating Commercial Expansion

Cycurion reports about $800,000 in annual contract spend from new commercial and public-health engagements that advance its healthcare and life-sciences strategy.

Rhea-AI Summary

Cycurion (CYCU) announced new commercial and public-health engagements totaling approximately $800,000 in annual contract spend. The work includes a pharmaceutical-industry engagement to support an AI Center of Excellence, a new National Association of County and City Health Officials (NACCHO) award, and additional commercial and public-health projects.

The company highlights these as the first public announcement of these awards and as evidence of its strategy to expand in commercial healthcare, life sciences, and other non-government sectors while maintaining its government and public-safety franchise. Scope spans business continuity, disaster recovery, technology and cybersecurity assessments, program management, organizational change management, and AI operating capability.

Positive

• Approximately $800,000 in new annual contract spend across multiple engagements
• First public announcement of commercial wins, including a pharmaceutical AI Center of Excellence engagement
• New NACCHO award deepens relationship and adds public-health revenue
• Advances diversification into commercial healthcare, life sciences, and other non-government sectors while maintaining government and public-safety work

Negative

• None.

Market reaction after commercial contract awards: CYCU +4.29%

+4.29% $3.16

15m delay

+4.29% Vs previous close

+7.8% Peak Tracked

$3.16 Last Price

$3.00 $3.45 Day Range

0.2x Rel. Volume

Following this news, CYCU has gained 4.29%, reflecting a moderate positive market reaction. Argus tracked a peak move of +7.8% during the session. Our momentum scanner has triggered 4 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $3.16.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

On August 17, CYCU rose 6.79% after the share-repurchase authorization. That comparison adds context...

Analysis

On August 17, CYCU rose 6.79% after the share-repurchase authorization. That comparison adds context to the new engagements, which emphasize execution rather than a completed financial outcome; subsequent filings could show whether commercial work improves operating results.

Key Figures

Annual contract spend: Approximately $800,000

1 metrics

Annual contract spend Approximately $800,000 Across announced pharmaceutical, NACCHO, commercial, and public-health engagements

Historical Context

5 past events · Latest: Aug 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 26	fundamentals and contracts	Positive	-29.5%	Reverse split announcement highlighted improved margins, acquisitions, contracts, and a revenue pipeline.
Aug 26	reverse stock split	Neutral	-29.5%	One-for-eight reverse split was scheduled to address Nasdaq minimum bid-price compliance.
Aug 19	patent protection	Positive	-5.5%	USPTO granted a patent extending protection for VuLink cross-activation technology.
Aug 17	share repurchase	Positive	+6.8%	Board authorized a discretionary share repurchase program of up to $500,000.
Aug 14	second-quarter earnings	Positive	-2.1%	Revenue and EPS exceeded consensus while gross margin improved and net debt declined.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Among the five selected events, four had negative 24-hour reactions and one had a positive reaction, indicating frequent post-news divergence.

Key Terms

business continuity, disaster recovery, organizational change management

3 terms

business continuity technical

"Scope across the engagements includes business continuity and disaster recovery"

Business continuity is the set of plans and actions a company uses to keep essential operations running during disruptions like natural disasters, cyberattacks, or supply problems — think of it as a backup plan or spare tire for the business. Investors care because strong continuity reduces the chance of lost revenue, surprise costs, and long outages, which helps protect cash flow, reputation, and the value of their investment.

disaster recovery technical

"Scope across the engagements includes business continuity and disaster recovery"

A plan and set of actions a company uses to restore its critical systems, data, facilities and operations after a major disruption such as a natural disaster, cyberattack or infrastructure failure. Investors care because strong disaster recovery reduces the chance of prolonged downtime, unexpected costs and lost revenue — like a business’s emergency backup and repairs that protect value, reputation and future cash flow.

organizational change management technical

"organizational change management, and AI operating capability"

Organizational change management is the structured process companies use to plan, communicate, and guide people through major shifts in strategy, systems, processes, or culture. It matters to investors because effective change management helps ensure projects meet timelines and budgets, preserves employee productivity and customer relationships during transitions, and reduces the risk that planned benefits or cost savings fail to materialize; think of it as managing a household renovation while keeping the house livable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

First public announcement of a pharmaceutical AI Center of Excellence engagement, a NACCHO award, and additional commercial and public-health work

MCLEAN, Va., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cycurion, Inc. (Nasdaq: CYCU) (“Cycurion” or the “Company”), a trusted leader in IT cybersecurity and AI-driven solutions, today announced several engagements totaling approximately $800,000 in annual contract spend. The work includes a pharmaceutical-industry engagement to support an AI Center of Excellence, a new award with the National Association of County and City Health Officials (NACCHO), and additional commercial and public-health engagements. This is the first public announcement of these awards.

This is the commercial expansion Cycurion told the market it was going after. The Company is building commercial healthcare and life-sciences work as a primary growth market, while continuing to run its government and public-safety franchise. Scope across the engagements includes business continuity and disaster recovery, technology and cybersecurity assessments, program management, organizational change management, and AI operating capability.

The announcement reflects the Company’s deliberate strategy — as previously communicated to the market — to accelerate expansion into commercial healthcare, life sciences, and other non-government sectors where demand for resilient IT, cybersecurity, and AI-enabled operating capability continues to grow.

“These wins are exactly the kind of commercial traction we told the market we were going after,” said L. Kevin Kelly, Chairman and Chief Executive Officer of Cycurion. “A pharmaceutical organization has engaged us to support its AI Center of Excellence. NACCHO has awarded new work. Customers are not paying for slogans. They are paying for resilience, cybersecurity, program delivery, and AI that has to run in a real operating environment. Each of these engagements puts us inside an organization that will need more of what we do. We are not dabbling in commercial. We are building it.”

What the Work Covers

Across the commercial and NACCHO-related engagements, Cycurion is supporting clients with:

• Business continuity and disaster recovery planning and execution
• Technology and cybersecurity assessments
• Program management for complex technology initiatives
• Organizational change management
• Support for an AI Center of Excellence for a pharmaceutical organization
  

The pharmaceutical AI Center of Excellence engagement is a commercial life-sciences win the Company has been building toward. The NACCHO award is being announced for the first time and deepens Cycurion’s existing relationship with the association, including its standing as a Diamond Affiliate Partner. Additional commercial and public-health work is included in the approximately $800,000 annual contract-spend total.

Why It Matters

The number is approximately $800,000 in annual contract spend. The signal is the market. These engagements convert a stated commercial strategy into work in pharmaceutical, healthcare, and public health, and they put Cycurion inside accounts that can grow. Government and public safety remain core. Commercial is a market Cycurion is going after.

The Company will continue to pursue additional commercial and non-government opportunities that fit its capabilities in cybersecurity, managed IT, program delivery, and AI-enabled transformation.

About Cycurion, Inc. 

Based in McLean, Virginia, Cycurion (Nasdaq: CYCU) is a forward-thinking provider of IT cybersecurity solutions and AI, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies LLC, Cloudburst Security LLC, and Cycurion Innovation, Inc., Cycurion serves government, healthcare, and corporate clients committed to securing the digital future. For more information, visit www.cycurion.com. 

Forward-Looking Statements 

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the operations and prospective growth of Cycurion’s business.

Certain statements in this press release that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Such statements include, but are not limited to, statements regarding the approximately $800,000 in aggregate annual contract spend associated with the new awards; the scope, timing and duration of the services to be provided under those awards; the Company’s ability to perform under the new contracts and to realize their anticipated benefits; the development of an AI Center of Excellence for a pharmaceutical organization; the expansion of the Company’s commercial healthcare, life sciences and other non-government business; the Company’s expectation that these engagements will lead to additional work with these clients; the deepening of the Company’s relationship with NACCHO and its member organizations; the Company’s ability to identify and win additional commercial and non-government opportunities; the continued execution on the Company’s backlog; and other statements that are not historical facts. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Cycurion and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to, risks related to customer performance and satisfaction, contract modifications, delays or terminations, and the Company’s ability to fulfill contractual obligations; the outcomes of the Company’s investigations, any potential legal proceedings, or the future performance of the Company’s stock. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K filed by Cycurion with the U.S. Securities and Exchange Commission. Cycurion anticipates that subsequent events and developments may cause its plans, intentions, and expectations to change. Cycurion assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Cycurion’s plans and expectations as of any subsequent date.

Cycurion Investor Relations: 
(888) 341-6680 
investors@cycurion.com 

Cycurion Media Relations: 
(888) 341-6680 
media@cycurion.com

FAQ

What did Cycurion (CYCU) announce about new contracts on September 3, 2026?

Cycurion announced several new engagements totaling approximately $800,000 in annual contract spend, including a pharmaceutical AI Center of Excellence engagement, a new NACCHO award, and additional commercial and public-health work.

How much new annual contract spend did Cycurion (CYCU) report in its latest announcement?

Cycurion reported approximately $800,000 in annual contract spend from recently secured engagements spanning pharmaceutical, healthcare, and public-health clients, including a pharmaceutical AI Center of Excellence project and a NACCHO award.

Which sectors are covered by the new Cycurion (CYCU) engagements?

The new engagements cover pharmaceutical, healthcare, life sciences, and public health. They include a pharmaceutical AI Center of Excellence, NACCHO-related work, and other commercial and public-health projects, while the company continues its government and public-safety franchise.

What services will Cycurion (CYCU) provide under these new contracts?

Cycurion will provide business continuity and disaster recovery, technology and cybersecurity assessments, program management for complex technology initiatives, organizational change management, and support for an AI Center of Excellence for a pharmaceutical organization.

How do the new contracts support Cycurion’s (CYCU) commercial strategy?

The company states these engagements convert its stated strategy into tangible commercial work in pharmaceutical, healthcare, and public health. They place Cycurion inside accounts that can grow, supporting expansion beyond government into non-government markets demanding resilient IT, cybersecurity, and AI-enabled operations.